Director Therapeutic Expertise Team
Leyla is a scientific , operational and strategic leader. She has 10+ years of experience and is a member of ReSViNET’s board of directors. Under her guidance, this talented and dedicated group of scientists and professionals can create a customized plan for the evaluation of your treatment at a global scale.
We presented the webinar COVID-19 lessons from pandemic to endemic. During this webinar Prof. Jerome H. Kim, Director General of the International Vaccine Institute (IVI), discussed:
– Pandemic preparedness – lessons learned
– Clinical Development for new COVID-19 vaccines
– Known and Unknown” Unknowns
Watch the replay now
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme to make new and improved vaccines accessible to low- and middle-income countries.
With a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, IVI works with other product development partners to take innovative vaccine technology from need to impact. IVI developed the world’s first low-cost oral cholera vaccine, manufactured by three different companies and pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI’s portfolio includes vaccines at all stages of pre-clinical and clinical development for diseases of global health importance such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, Hepatitis E, HPV, and COVID-19.
IVI is headquartered in Seoul, Republic of Korea with a European Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, and Finland provide state funding. For more information, please visit https://www.ivi.int.
On September 6, our partner ReSViNET presented the webinar: “RSV and Asthma” Prof Tina Hartert, MD, MPH shared her insights on RSV in relationship to asthma. Her study of almost two thousand children has identified that delay in early life ...
On May 10, our partner ReSViNET presented the webinar: Progress in RSV Vaccines and Monoclonal Antibodies In this webinar, Professor Barney Graham, MD, PhD, shared his views on the lanscape of RSV therapeutics. The webinar was hosted by Prof. D...
On April 26, we presented the webinar: RSV vaccine development for all ages, what lies ahead of us? In this webinar, Prof. Louis Bont, shared his views on the burden of RSV infections across generations and the latest advancements in monocl...